- ISIN
- US25056L1035
- CUSIP
- 25056L103
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 26, 2021
Highlights
- Market Cap
- $841.65M
- Enterprise Value
- $831.08M
- EPS (TTM)
- -$1.20
- EBITDA (TTM)
- -$73.49M
- Year Range
- $3.33 - $17.25
- Target Price
- $15.67
- ROA (TTM)
- -30.25%
- ROE (TTM)
- -31.97%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
DSGN Performance Chart
Design Therapeutics, Inc. (DSGN) is up 46.1% since the beginning of the year. At $14 per share, DSGN is trading 20.6% below its 52-week high of $17. Investors who bought $1,000 worth of DSGN shares 5 years ago would now be looking at an investment worth $601.
Loading charts...
Returns By Period
Design Therapeutics, Inc. (DSGN) has returned 46.06% so far this year and 266.31% over the past 12 months.
Design Therapeutics, Inc.
- 1D
- 10.13%
- 1M
- 24.89%
- YTD
- 46.06%
- 6M
- 37.55%
- 1Y
- 266.31%
- 3Y*
- 34.11%
- 5Y*
- -9.69%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
DSGN Monthly Returns History
Based on dividend-adjusted daily data since Mar 26, 2021, DSGN's average daily return is +0.12%, while the average monthly return is +1.63%. At this rate, an investment would double in approximately 3.6 years.
Historically, 53% of months were positive and 47% were negative. The best month was Jul 2024 with a return of +52.2%, while the worst month was Aug 2023 at -69.5%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, DSGN closed higher 50% of trading days. The best single day was Mar 26, 2021 with a return of +48.2%, while the worst single day was Aug 15, 2023 at -70.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 8.85% | 2.25% | 1.92% | 27.82% | -22.94% | 30.73% | 46.06% | ||||||
| 2025 | -21.39% | 0.21% | -20.58% | 25.91% | -23.25% | -9.65% | 14.84% | 42.89% | 36.17% | -11.02% | 40.15% | -0.11% | 52.03% |
| 2024 | -10.57% | 17.30% | 44.96% | -12.66% | 15.06% | -17.28% | 52.24% | -6.86% | 13.26% | -2.60% | 14.50% | 2.83% | 132.83% |
| 2023 | -23.49% | -9.94% | -18.39% | 11.79% | -12.71% | 11.90% | 29.21% | -69.53% | -4.84% | -13.56% | 17.65% | 10.42% | -74.17% |
| 2022 | -40.96% | 7.36% | 19.01% | -26.07% | 4.52% | 12.18% | 40.14% | 3.26% | -17.47% | -6.58% | -10.37% | -26.71% | -52.08% |
| 2021 | 6.79% | -12.27% | -0.11% | -24.08% | -22.17% | 1.55% | -6.55% | 6.74% | 6.76% | 27.90% | -23.54% |
Benchmark Metrics
Design Therapeutics, Inc. has an annualized alpha of 10.21%, beta of 1.47, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since March 26, 2021.
- This stock participated in 195.77% of S&P 500 Index downside but only 115.84% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 10.21%
- Beta
- 1.47
- R²
- 0.08
- Upside Capture
- 115.84%
- Downside Capture
- 195.77%
Return for Risk
Risk / Return Rank
DSGN ranks 94 for risk / return — in the top 94% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Design Therapeutics, Inc. (DSGN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| DSGN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.22 | ||
| Sortino ratioReturn per unit of downside risk | +0.47 | ||
| Omega ratioGain probability vs. loss probability | 1.42 | 1.37 | +0.05 |
| Calmar ratioReturn relative to maximum drawdown | 7.54 | 2.78 | +4.75 |
| Martin ratioReturn relative to average drawdown | 22.15 | 12.44 | +9.71 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Design Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Design Therapeutics, Inc. was 95.20%, occurring on Nov 9, 2023. The portfolio has not yet recovered.
The current Design Therapeutics, Inc. drawdown is 66.98%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -95.20%Nov 2023 | 2y 7mo | — | 5y 2moMar 2021 - now |
Drawdown Indicators
| DSGN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.20% | -56.78% | -38.42% |
Max Drawdown (1Y)Largest decline over 1 year | -35.59% | -9.10% | -26.49% |
Max Drawdown (3Y)Largest decline over 3 years | -75.55% | -18.90% | -56.65% |
Max Drawdown (5Y)Largest decline over 5 years | -92.22% | -25.43% | -66.79% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -66.98% | -1.80% | -65.18% |
Average DrawdownAverage peak-to-trough decline | -76.52% | -10.71% | -65.81% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.09% | 2.03% | +10.06% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Design Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Design Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for DSGN in comparison with other companies in the Biotechnology industry. Currently, DSGN has a P/B value of 3.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with DSGN
Add Design Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with DSGN